Table 1.

Clinical characteristics of study participants

		PHS	Gelb Center	FHCRC
Cases/controls (n)		1438 (1347)*/1462	3714/--	1308/1266
Deaths/long-term survivors (n)		187/584	250/158	56/526
Age at diagnosis (n)		1438	3714	1308
mean (st. dev.)		70.5 (7.7)	62.0 (8.2)	59.9 (7.0)
Gleason (n)		1270	3458	1308
<7 (%)		51.3	41.1	57.3
7 (%)		33.5	37.4	33.1
>7 (%)		15.2	21.5	9.7
Pathologic stage (n)		469	1452	740
T2		72.7	67.5	71.3
T3/T4		27.3	32.5	28.7
PSA at diagnosis (n)		687	3278	1177
median (Q1, Q3)		7.6 (5.4, 13.0)	6.5 (4.7, 11.0)	6.2 (4.6, 9.6)

^*1347 cases were part of the PHS matched case-control study and included in the analysis for prostate cancer risk